Immunoglobulin Fab Fragments
"Immunoglobulin Fab Fragments" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
| Descriptor ID |
D007140
|
| MeSH Number(s) |
D12.644.541.500.650 D12.776.124.486.485.680.650 D12.776.124.790.651.680.650 D12.776.377.715.548.680.650
|
| Concept/Terms |
Immunoglobulin Fab Fragments- Immunoglobulin Fab Fragments
- Fab Fragments, Immunoglobulin
- Immunoglobulins, Fab Fragment
- Fab Fragment Immunoglobulins
- Fragment Immunoglobulins, Fab
- Immunoglobulin Fab Fragment
- Fab Fragment, Immunoglobulin
- Fab Immunoglobulin Fragments
- Immunoglobulin Fragments, Fab
- Fab Fragments
- Immunoglobulins, Fab
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Fab Fragments".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Fab Fragments".
This graph shows the total number of publications written about "Immunoglobulin Fab Fragments" by people in this website by year, and whether "Immunoglobulin Fab Fragments" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 1 | 3 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin Fab Fragments" by people in Profiles.
-
Shaheen A, Ashkenazy N, Magraner M, Patel NA, Fortun J, Rosenfeld PJ, Schwartz SG, Haddock LJ, Dubovy SR, Sridhar J, Yehoshua Z, Kovach JL, Townsend JH, Smiddy WE, Flynn HW, Yannuzzi NA. Faricimab in Previously Treated Eyes With Neovascular Age-Related Macular Degeneration: An Assessment of Durability and Treatment Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2024 09; 55(9):504-509.
-
Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc Natl Acad Sci U S A. 2018 11 20; 115(47):12023-12027.
-
Bournazos S, Ravetch JV. Anti-retroviral antibody Fc?R-mediated effector functions. Immunol Rev. 2017 01; 275(1):285-295.
-
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell. 2016 Jun 16; 165(7):1609-1620.
-
Fertala J, Steplewski A, Kostas J, Beredjiklian P, Williams G, Arnold W, Abboud J, Bhardwaj A, Hou C, Fertala A. Engineering and characterization of the chimeric antibody that targets the C-terminal telopeptide of the a2 chain of human collagen I: a next step in the quest to reduce localized fibrosis. Connect Tissue Res. 2013; 54(3):187-96.
-
Popescu AM, Weintraub WS. Outpatient percutaneous coronary interventions: hospital and health system costs saving while maintaining patient safety. JACC Cardiovasc Interv. 2010 Oct; 3(10):1020-1.
-
Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010 Sep 30; 467(7315):591-5.
-
Kuhn JA, Nochumson J. Operative probe scintimetry with indium and technetium for colorectal cancer. J Surg Oncol. 2007 Sep 15; 96(4):290-6.
-
Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
-
Cole JH, Weintraub WS. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention? Circulation. 2003 Dec 09; 108(23):2831-3.